Managed Healthcare Executive

FDA Approves Eydenzelt, Additional Eylea Biosimilar

Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease ...
Pharmaceutical Technology on MSN

FDA approves Celltrion’s Eydenzelt for eye diseases

Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...
Ophthalmology Times

REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD

REGENXBIO completed enrollment in its ATMOSPHERE and ASCENT trials that will be evaluating surabgene lomparvovec (sura-vec, ...
MPR

Aflibercept Biosimilar Eydenzelt Gets FDA Approval

The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).

Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Ex…

Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies ...
European Medical Journal

TGF-β1 Blockade Restores Bone Marrow Endothelial Function

New research links TGF-β1 to maladaptive bone marrow endothelial cell repair and shows that blocking its pathway can restore haematopoietic function after transplant.
Nanowerk

Light-driven nanomotors clear blood clots and restore vessel health

Light responsive nanomotors dissolve blood clots and repair vessel tissue by combining catalytic activity, targeted motion, and gentle heating for coordinated thrombolysis and endothelial regeneration ...